Entasis Therapeutics Holdings Inc. (ETTX)
| Market Cap | 175.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.57M |
| Shares Out | 47.31M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 198,706 |
| Open | 3.71 |
| Previous Close | 3.72 |
| Day's Range | 3.64 - 3.84 |
| 52-Week Range | 1.58 - 3.88 |
| Beta | 1.91 |
| Analysts | Buy |
| Price Target | 6.00 (+60.0%) |
| Est. Earnings Date | Nov 4, 2021 |
About ETTX
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinic...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ETTX stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 60.00% from the latest price.
News
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibac...
Making Money With Penny Stocks During a Stock Market Crash
Trading penny stocks in a down market? Here's three tips and tricks to use in your search The post Making Money With Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks...
Why Are Entasis Therapeutics Shares Moving Higher On Thursday?
Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) stock is up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of ...
Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens Publication Details the Discovery and Preclinical Profile of ETX046...
Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-Management to Host Conference Call on August 12 at 8am ET-
Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
– Virtual Event to be Held Tuesday, August 24 at 10am Eastern Time –
Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial O...
– Significant commercial strategy and product launch experience – – ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 –
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and ...
WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at Wo...
WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
5 Top Penny Stocks Insiders Decided To Buy In June 2021
Penny stocks to watch right now after insiders bought in June. The post 5 Top Penny Stocks Insiders Decided To Buy In June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing –
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacte...
Entasis Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
– Phase 3 ATTACK registration trial more than three-quarters complete – – ATTACK topline data readout expected second half of 2021 – – Zoliflodacin Phase 3 trial adds clinical trial sites, continues enr...
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics to Participate in A.G.P.'s Virtual Healthcare Symposium
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update
WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibact...
Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antib...
Entasis Therapeutics Announces $25 Million Private Placement
Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial
Entasis Therapeutics to Participate in Upcoming Healthcare Conferences
WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba...
Entasis Therapeutics (ETTX) Jumps: Stock Rises 5.4%
Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Entasis Therapeutics Awarded Contract from National Institutes of Health
WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba...
Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antiba...